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ONS-3010 is being developed by Oncobiologics Inc. (Cranbury, NJ, USA) as a  biosimilar 
of Humira®. This randomized, double blind, single-center phase I study (EudraCT 
registration # 2013-003551-38) was performed to demonstrate pharmacokinetic (PK) 
biosimilarity between two reference products (Humira® EU and US) and ONS-3010 in 
healthy volunteers, and to compare the safety and immunogenicity profiles. In addition, 
the intended pharmacological activity was assessed and compared by application of a 
whole blood challenge. Hundred ninety-eight healthy volunteers received a single 40 mg 
subcutaneous dose of ONS-3010, Humira® EU, or US. The pharmacodynamic effects 
were assessed by lipopolysaccharide (LPS)/aluminum hydroxide whole blood challenges 
(n = 36; n = 12 per treatment arm; male:female, 1:1). Equivalence was demonstrated 
on the PK endpoints (AUC0–inf, Cmax, and AUC0–last) based on bounds of 80–125% for the 
ratio of the geometric means (ONS-3010/Humira®). The immunogenicity profiles were 
comparable between treatment groups, and there were no indications for differences in 
routine safety parameters. Administration of adalimumab resulted in the observation of 
dramatically reduced tumor necrosis factor-α (TNFα) levels upon stimulation with LPS/
aluminum hydroxide (>99%), with no differences between the three treatment groups 
in terms of magnitude or duration. Adalimumab also resulted in a reduction of LPS/alu-
minum hydroxide-induced interleukin (IL)-8 release (maximally 30%), suggested to have 
a causal relationship with the anti-TNFα treatment. LPS/aluminum hydroxide-induced 
release of IL-1β and IL-6 was not inhibited by anti-TNFα treatment. Taken together, these 
Abbreviations: ANOVA, analysis of variance; AUC, area under the curve; AUC0–last, AUC zero to last measurement point; 
AUC0–inf, AUC zero to infinity; BLOQ, below the limit of quantification; CI, confidence interval; Cmax, maximum concentration; 
EC50, half maximal effect concentration; ELISA, enzyme-linked immunosorbent assay; EMA, European Medicines Agency; 
Emax, maximal effect; FDA, Food and Drug Administration; IFNγ, interferon-γ; IL-1β, interleukin-1β; IL-6, interleukin-6; 
IL-8, interleukin-8; IL-12, interleukin-12; IL-18, interleukin-18; Kel, elimination rate constant; LPS, lipopolysaccharide; MSD, 
Meso Scale Discovery; NALP3, NACHT, LRR, and PYD domains-containing protein 3; NLRP3, NACHT, LRR, and PYD 
domains-containing protein 3 encoding gene; NFκB, nuclear factor κ-B; NK, natural killer; PD, pharmacodynamics; PK, 
pharmacokinetics; t1/2, terminal half-life; TLR4, toll-like receptor-4; Tmax, time at observed maximum concentration; TNFα, 
tumor necrosis factor-α; TNFR1, TNF receptor type 1; TNFR2, TNF receptor type 2.
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data are promising for the further clinical development of ONS-3010, demonstrate the 
relevance of the LPS/aluminum challenge to monitor Humira® effects, and emphasize 
the value of whole blood challenges for monitoring of proximal drug effects in healthy 
volunteers, and potentially in the target population.
Keywords: tumor necrosis factor-alpha, lipopolysaccharide, pharmacodynamics, pharmacokinetics, 
bioequivalence
inTrODUcTiOn
Biotherapeutic adalimumab (Humira®, AbbVie Inc., North 
Chicago, IL, USA) is a recombinant human IgG1 monoclonal 
antibody binding tumor necrosis factor-α (TNFα), which is one 
of the earliest and most potent cytokines mediating inflamma-
tory responses (1). TNFα is produced primarily by activated 
macrophages but also by CD4+ lymphocytes, natural killer (NK) 
cells, neutrophils, mast cells, eosinophils, and neurons. Binding 
of TNFα to its receptor, TNF receptor type 1 (TNFR1) or TNF 
receptor type 2 (TNFR2), results in downstream activation of 
caspase, nuclear factor κ-B (NFκB), JNK, or MAPK pathways 
(2). TNFα is an autocrine stimulator as well as a potent paracrine 
inducer of interleukin (IL)-1, IL-6, IL-8, and other inflammatory 
cytokines (3). Blockage of TNFα therefore not only results in 
inhibition of direct TNF effects but also has a more general effect 
on inflammation (3, 4). Inactivation of TNFα has proven to be 
important in downregulating the inflammatory and immune 
reactions associated with rheumatoid arthritis and other autoim-
mune conditions (3, 5–10). Adalimumab binds specifically to 
TNFα, blocks its interaction with TNFR1 and TNFR2, and lyses 
surface TNFα-expressing cells in vitro in the presence of comple-
ment. Adalimumab also modulates biological responses induced 
or regulated by TNFα, including changes in the levels of adhesion 
molecules responsible for leukocyte migration (11).
The development of products that are designed as a biosimilar 
of the original licensed product has gained interest over recent 
years because of expiring patents of originator’s biotherapeutic 
products. This is also the case for Humira®: the patent is expected 
to expire in December 2016 in the US and in April 2018 in the 
EU. Per FDA and EMA guidelines, demonstration of biosimilar-
ity between test and reference biotherapeutics comprises quality 
characteristics, pharmacokinetic (PK) properties, biological 
activity, safety, and efficacy (12–16). Although the FDA and EMA 
recommend to include pharmacodynamic (PD) endpoints in 
biosimilarity studies whenever feasible, no guidance is provided 
on the clinical development phase in which PD endpoints may be 
included. Assessing PD effects only in advanced phases of clinical 
development bears the risk of late discovery of non-biosimilarity, 
as was the case for Alpheon, recombinant human IFNα-2a (17). 
The addition of PD endpoints in early biosimilarity studies could 
add valuable information for the evaluation of overall compara-
bility of products.
ONS-3010 is being developed by Oncobiologics Inc. (Cranbury, 
NJ, USA) as a biosimilar of Humira®. A phase I clinical study 
was performed to demonstrate PK biosimilarity between two 
reference products (the EU and US approved forms of Humira®) 
and ONS-3010 in healthy volunteers, and to compare the safety 
and immunogenicity profile of ONS-3010 with the two registered 
forms of Humira®. In addition, the intended pharmacological 
activity of the three products was assessed and compared by 
application of a whole blood challenge. In this model, robust 
activation of toll-like receptor (TLR)4-driven NFkB signaling 
and the NALP3/NLRP3 inflammasome pathway is induced in 
circulating immune cells by incubation of freshly isolated whole 
blood with lipopolysaccharide (LPS) and aluminum hydroxide 
(18–22). NFkB signaling generates an inflammatory response 
characterized by TNFα, IL-6, IL-8, IL-1β, and IFNγ release (23), 
whereas inflammasome activation results in further enhancement 
of IL-1β responses and secretion of IL-18 and IL-33 (21, 24, 25). 
TLR4 and inflammasome pathways are implicated in the patho-
genesis of autoimmune diseases such as rheumatoid arthritis 
(26–28), and TNFα blockade specifically alters these responses by 
its effect on NFkB, playing a key role in NLRP3 priming (26, 29). 
Application of LPS/aluminum hydroxide whole blood challenges 
in this healthy volunteer trial not only allowed early assessment 
of the intended PD activity of ONS-3010 in comparison with the 
two reference products but also provided mechanistic insight into 
the secondary effects of TNFα blockade.
MaTerials anD MeThODs
study Design
The bioequivalence study was a randomized, double blind, 
single-center phase I study with three treatment arms: ONS-
3010 (Oncobiologics Inc., Cranbury, NJ, USA) and reference 
products Humira® EU (AbbVie, Berkshire, UK) and Humira® 
US (AbbVie, North Chicago, IL, USA, EudraCT registration # 
2013-003551-38). The study was performed in a total number of 
198 volunteers, who were deemed healthy and screened negative 
for (latent) tuberculosis, acute infectious disease, malignancy, 
and autoimmune disorders. All women of child bearing potential 
and all males had to practice effective contraception during the 
study and had to be willing and able to continue contraception 
for at least 5 months after dose administration of study treatment 
to be able to participate in the study. In addition, the subjects had 
to have a negative screening result for Hepatitis B/C and HIV, 
and smoking was prohibited during the complete study period. 
Sixty-six subjects per treatment arm received a single subcutane-
ous dose of 40 mg TNFα antibody according to a randomization 
schedule, which was stratified for gender. PK, immunogenicity, 
and safety analyses were conducted for all 198 study participants. 
The PD effects of these three TNFα blockers were assessed by 
LPS/aluminum hydroxide whole blood challenges, for which 36 
subjects were randomly selected from the 3 treatment arms (6 
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male and 6 female subjects per arm). Before the LPS/aluminum 
hydroxide whole blood challenges were implemented as a PD 
bioassay in the clinical study, the effect of TNFα blockade on the 
LPS/aluminum hydroxide-induced inflammatory response was 
explored in an in vitro experiment (see below).
The phase I clinical trial was conducted in accordance with 
the Declaration of Helsinki and Guideline for Good Clinical 
Practice and was approved by the Independent Ethics Committee 
of the Foundation “Evaluation of Ethics in Biomedical Research,” 
Assen, The Netherlands.
Pharmacokinetic analysis
Plasma concentrations of adalimumab (ONS-3010, Humira® 
EU, or Humira® US) following a single 40  mg subcutaneous 
dose administration were assessed in blood samples col-
lected in 4  mL SSTTM Gel and Clot Activator tubes (Becton 
Dickinson), from day 1 (pre-dose) up to day 71 (post-dose). An 
electrochemiluminescence assay (Meso Scale Discovery, MSD) 
was developed and validated to measure the concentration 
of adalimumab in human serum. Data values below the limit 
of quantification (BLOQ, 250  ng/mL) were set to 125  ng/mL 
(50% of the limit of quantification, LOQ) for summarizing and 
graphical purposes. If more than one-third of all values were 
BLOQ for a specific time point/treatment combination, the data 
point was not included in the summary/graph. For PK analysis, 
BLOQ data points were set to zero when not embedded between 
two measurable data points (i.e., >BLOQ) and occurring prior 
to Tmax. BLOQ data points were excluded from PK analysis when 
not embedded between two measurable data points and occur-
ring after Tmax, or when embedded between two measurable data 
points.
lPs/aluminum hydroxide  
Whole Blood challenge
Preceding the phase I clinical trial, the effect of in vitro TNFα 
blockade on LPS/aluminum hydroxide-induced cytokine 
release in whole blood samples was explored. Blood specimens 
were obtained from four healthy male volunteers in sodium 
heparin tubes (Becton Dickinson). Fresh whole blood was 
(pre-)incubated in 96-well plates with Humira® EU at 37°C at 
5% CO2. The Humira® concentration ranged from 0.3125 to 
10 μg/mL, which was based on the expected maximum concen-
trations of 4.7 ± 1.6 μg/mL, observed after a single administra-
tion of 40 mg (11). After 90 min, 2 ng/mL LPS (Sigma-Aldrich, 
St Louis, MO, USA) and 100 μg/mL Alhydrogel 85 (aluminum 
hydroxide, Brenntag, Frederikssund, Denmark) were added 
to the samples followed by an additional incubation period 
of 20 h. In the clinical study, LPS/aluminum hydroxide whole 
blood challenges were performed in a subset of study partici-
pants, pre-dose (day 1) and on day 5, day 15, day 29, and day 
64. Conditions for the whole blood challenges were similar as 
for the in vitro experiment above, except for the fact that the 
incubations were performed in a larger volume (2  mL), and 
no pre-incubation with Humira® EU was performed. Cytokine 
release was measured in the culture supernatants by an elec-
trochemiluminescence assay (MSD, V-plex; TNFα, IL-1β, IL-6, 
IL-8, and IFNγ, intra- and inter-assay variation: <10%) or 
ELISA (R&D Systems; IL-18).
immunogenicity
Blood samples for analysis of adalimumab-associated antibodies 
against ONS-3010 and Humira® were collected in 4 mL SST™ 
Gel and Clot Activator tubes (Becton Dickinson). A bridging 
ELISA assay was used to measure anti-adalimumab antibodies in 
serum samples by electrochemiluminescence. Positive immuno-
genicity samples were further investigated to confirm the speci-
ficity of binding. If a sample was confirmed positive for specific 
anti-adalimumab antibodies, the neutralizing capacity of these 
antibodies was investigated. Binding specificity was determined 
by competitive inhibition with 5 mg/mL of unlabeled ONS-3010; 
samples with an inhibition >20.7% were confirmed positive for 
anti-drug antibody. Assay sensitivity was 2.463 ng/mL and inter-
run assay precision 5.143–11.354%.
routine safety assessments
Pre-dose (day 1) and on day 2 (hematology only), day 4, day 8, 
day 36, and day 72, blood and urine samples were collected for 
routine hematology, biochemistry, and urinalysis safety param-
eter assessments. In addition, general safety measures such as 
vital signs, electrocardiography, and symptoms were assessed 
throughout the study.
Data analysis
Demographic and PD data were summarized and presented by 
graphical and tabular presentations. For the inhibition of TNFα 
and IFNγ release after incubation with LPS/aluminum hydroxide 
and increasing adalimumab concentrations in  vitro, a model 
was fitted to the data in R (v2.15.2, R Foundation for Statistical 
Computing, Vienna, Austria, 2012) and described by a maximal 
effect (Emax) and half maximal effect concentrations (EC50).
A non-compartmental analysis was performed to describe the 
PK of the antibodies using SOFTWARE. The area under the curve 
(AUC) was computed from zero to the last measurement point 
(AUC0–last). If the terminal phase was sufficiently well character-
ized (at least three data points after Tmax and a linear regression 
r2 ≥0.5), the terminal half-life (t1/2) and the AUC zero to infinity 
(AUC0–inf) were estimated. PK profiles of the investigational 
product (ONS-3010) and the reference products (Humira® EU 
and Humira® US) were compared using general linear model 
procedures in SAS®. An analysis of variance (ANOVA) was 
performed on the untransformed elimination rate constant (Kel), 
apparent terminal elimination half-life (t1/2 el), and ln-transformed 
AUC0–last, AUC0–inf, and Cmax. The ANOVA model included treat-
ment as a fixed effect. The ratio of means with the 90% geometric 
confidence interval (CI) was calculated for AUC0–last, AUC0–inf, 
and Cmax. Bioequivalence was evaluated in accordance with 
EMA and FDA guidelines on the investigation of bioequivalence 
(30, 31). The hypothesis of bioequivalence for the PK parameters 
AUC0–last, AUC0–inf, and Cmax was supported with 90% CI for the 
relative geometric means ratio fully enclosed in the equivalence 
bounds of 80–125%.
TaBle 1 | Demographics and baseline characteristics.
humira® eU humira® Us Ons-3010
age (years)
N 66 66 66
Mean (SD) 25.4 (8.4) 25.6 (9.0) 25.9 (9.3)
height (cm)
N 66 65 66
Mean (SD) 175.8 (8.6) 176.8 (9.5) 177.3 (8.4)
Weight (kg)
N 66 66 66
Mean (SD) 72.0 (11.1) 72.4 (11.5) 71.5 (9.4)
BMi (kg/m2)
N 66 66 66
Mean (SD) 23.2 (2.6) 23.1 (2.6) 22.7 (2.2)
sex
Female 36 (55%) 36 (55%) 36 (55%)
Male 30 (45%) 30 (45%) 30 (45%)
race
Asian 2 (3%) 0 (0%) 1 (2%)
Black or African American 7 (11%) 1 (2%) 5 (8%)
Hispanic or Latino 0 (0%) 2 (3%) 0 (0%)
White 50 (76%) 56 (85%) 58 (88%)
Mixed 6 (9%) 7 (11%) 2 (3%)
Other 1 (2%) 0 (0%) 0 (0%)
FigUre 1 | subject disposition.
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resUlTs
Demographics
A total number of 90 male and 108 female subjects aged between 
18 and 55 years, with a BMI of 19–29 kg/m2 and a body weight 
>50 kg were enrolled in the clinical trial with both sexes equally 
divided over the three treatment groups (ONS-3010 and Humira® 
EU/US, Figure 1; Table 1).
Pharmacokinetic analysis
Five subjects (four Humira® US; one Humira® EU) had an 
incomplete PK profile as a result of early study termination, and 
therefore PK parameters could not be determined accurately. 
These participants were excluded from the statistical analysis on 
total exposure parameters (e.g., AUC0–last). Two of these subjects 
had a PK profile up to 7 and 8 days, based on which Cmax and 
Tmax could be determined, and these data were included in the 
statistical analysis (Table 2).
Subcutaneous administration of adalimumab resulted in a 
steady increase in plasma concentrations starting at approximately 
36 h post-dose to reach a maximum concentration after 6–7 days, 
followed by a log-linear decrease and a non-linear decrease once 
the plasma concentration reached lower levels, similar to other 
monoclonal antibodies (Figure 2). Large variability in antibody 
concentration was observed between subjects during the elimina-
tion phase, with some subjects having adalimumab plasma con-
centration levels BLOQ (<250 ng/mL) 5 weeks after dosing, while 
others continued to have measurable levels up to the last study 
visit (day 71). On the primary PK endpoints, AUC0–inf and Cmax, 
equivalence was demonstrated based on bounds of 80–125% for 
the ratio of the geometric means (ONS-3010/Humira®; Table 3). 
Equivalence was also demonstrated for secondary PK endpoint 
AUC0–last.
lPs/aluminum hydroxide Whole Blood 
challenge
In a separate experiment preceding the clinical study, the effect 
of in vitro TNFα blockade on LPS/aluminum hydroxide-induced 
cytokine release in whole blood samples was explored. Addition 
of adalimumab to the LPS/aluminum hydroxide-triggered 
whole blood samples resulted in dramatically reduced TNFα 
levels measured in the culture supernatant. An average reduction 
FigUre 2 | adalimumab concentration-time profile for Ons-3010, 
humira® eU, and humira® Us with sD; vertical line at day 1 denotes 
dosing.
TaBle 2 | non-compartmental pharmacokinetic analysis.
Ons-3010 (n = 66) humira® eU (n = 66) humira® Us (n = 66)
AUC0–inf (ng × h/mL) 2,680,234 (995,883) 2,631,077 (1,077,199) 2,577,967 (1,112,632)
AUC0–last (ng × h/mL) 2,325,364 (870,647) 2,376,523 (891,150) 2,304,145 (941,728)
Cmax (ng/mL) 3869 (842) 3898 (987) 3692 (1030)
Tmax (h) 146 (59) 134 (70) 152 (82)
t1/2 (h) 317 (191) 307 (178) 318 (194)
Mean (SD).
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in TNFα level of 97 ±  0.6% was observed already at the low-
est adalimumab concentration evaluated (0.3125  μg/mL), as 
compared to the LPS/aluminum hydroxide only samples. With 
increasing concentrations of adalimumab, further reductions 
in TNFα levels were measured, up to 99 ±  0.1%. In addition, 
TNFα blockade affected the LPS/aluminum hydroxide-induced 
release of IFNγ with a maximal reduction of 93 ± 4% observed 
at an adalimumab concentration of 10 μg/mL. The adalimumab 
concentration-effect curves for TNFα and IFNγ are presented in 
Figure 3, with an Emax of 99 and 97% and an EC50 of 0.006 and 
0.6 μg/mL for TNFα and IFNγ, respectively. Increasing concen-
trations of adalimumab did not affect the release of IL-6, IL-1β, 
and IL-18 following LPS/aluminum hydroxide stimulation of 
whole blood (data not shown).
In the clinical study, adalimumab treatment resulted in a more 
than 99% reduction in measurable TNFα levels in LPS/aluminum 
hydroxide-triggered whole blood samples (Figure  4A). This 
effect was maximal at the first time point investigated (day 5) and 
lasted until at least 3  weeks post-dose. Thereafter, TNFα levels 
started to return to baseline with individual time courses depend-
ing on the adalimumab plasma concentration. On average, TNFα 
levels were still approximately 85% reduced at the last time point 
investigated (day 64). The reduction in TNFα levels did not differ 
between the three treatment groups.
Lipopolysaccharide/aluminum hydroxide-induced release 
of IL-1β and IL-6 was not inhibited by TNFα blockade 
(Figures  4B,C). For all treatment groups, a slight increase 
over baseline cytokine levels was observed on day 29, both for 
IL-1β (50, 25, and 17% for treatment ONS-3010, Humira® EU, 
and Humira® US, respectively) and IL-6 (25, 29, and 19%). 
Administration of adalimumab resulted in a reduction of LPS/
aluminum hydroxide-induced IL-8 release (Figure 4D). Minor 
differences were observed between treatment groups, with maxi-
mal reductions observed on day 5 [ONS-3010, −24% (CV 56%)] 
and day 15 [Humira® EU, −29% (CV 28%); Humira® US, −30% 
(CV 44%)], and a return to baseline levels between day 29 and day 
64. Whereas adalimumab inhibited LPS/aluminum hydroxide-
induced IFNγ release in the preclinical in vitro experiment, this 
effect could not be confirmed in the clinical study. IFNγ release 
was highly variable between subjects and BLOQ (<114 pg/mL) in 
the baseline samples of 21 out of the total number of 36 partici-
pants. IFNγ release strongly differed between males and females 
with mean baseline values of 1308 ± 1803 and 144 ± 278 pg/mL, 
respectively. Also, for the other cytokines (TNFα, IL-1β, IL-6, 
and IL-8) sex differences were observed, but to a lesser extent 
(cytokine release on average 1.6-fold higher in the male subjects, 
data not shown).
immunogenicity and immune cell counts
The immunogenicity profiles were well comparable between the 
ONS-3010, Humira® EU, and Humira® US treatment groups for 
the confirmed and neutralizing antibodies (Table 4).
Adalimumab administration resulted in a mild decrease 
in neutrophil count, amounting maximally 15–20% at day 8, 
and returning to baseline levels after 5  weeks (Figure  5A). 
Furthermore, adalimumab administration induced a mild 
increase in lymphocyte count, peaking 3 days after dose admin-
istration (Figure 5B). There were no indications for differences 
between treatment groups in neutrophil and lymphocyte cell 
counts over time.
DiscUssiOn
A phase I clinical study was performed to demonstrate bio-
similarity between ONS-3010 and two reference adalimumab 
products (the EU and US approved forms of Humira®) in healthy 
volunteers. For the PK endpoints (AUC0–inf, Cmax, AUC0–last) 
equivalence was demonstrated between ONS-3010 and the 
marketed products, based on bounds of 80–125% for the ratio of 
the geometric means (ONS-3010/Humira®). The immunogenic-
ity profiles were comparable between treatment groups for the 
confirmed and neutralizing antibodies, and there were no indica-
tions for differences between treatment groups in routine safety 
parameters, including neutrophil and lymphocyte cell counts. 
The adverse events (AEs), which were reported most frequently 
(probably, possibly, or unlikely related to treatment) were a 
FigUre 3 | Mean reduction of in vitro TnFα and iFnγ release (%, with 
sD) after lPs/aluminum hydroxide stimulation and incubation with 
increasing concentrations of adalimumab; curve fit presented as 
dotted line.
TaBle 3 | non-compartmental pharmacokinetic analysis – contrasts of anOVa.
humira® eU vs. humira® Us Ons-3010 vs. humira® Us Ons-3010 vs. humira® eU
contrast 90% ci p-value contrast 90% ci p-value contrast 90% ci p-value
AUC0–inf (ng × h/mL) 1.04 0.92–1.17 0.6365 1.06 0.94–1.20 0.4061 1.03 0.91–1.16 0.7141
AUC0–last (ng × h/mL) 1.05 0.92–1.20 0.5118 1.01 0.89–1.15 0.8705 0.96 0.85–1.09 0.6160
Cmax (ng/mL) 1.07 0.99–1.15 0.1811 1.06 0.98–1.15 0.1899 1.00 0.92–1.08 0.9746
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a reduced production of IFNγ following the use of TNFα blockers. 
However, the underlying mechanism for the observed inhibition 
is not fully elucidated (32–34). IFNγ can be produced by a variety 
of cells including T- and B-lymphocytes, antigen-presenting cells, 
and NK cells (35). NK cells are probably an important source 
of IFNγ in our model. IFNγ production is NFκB-driven and 
supported by IL-12 and IL-18 (36–38). TNFα may act synergisti-
cally with these cytokines, explaining the reduced IFNγ release 
observed in our experiment.
In contrast to the effect on IFNγ release, in vitro TNFα blockade 
did not modulate the release of IL-1β, IL-6, and IL-18. Although 
TNFα-induced NFκB signaling drives transcription of various 
cytokines, the unaffected IL-1β, IL-6, and IL-18 release upon 
TNFα blockade suggests that primary LPS-driven responses are 
sufficient to induce maximal cytokine release, and that secondary 
signaling via LPS-induced TNFα does not augment the LPS-
driven response.
The adalimumab induced reduction in TNF levels upon stim-
ulation with LPS/aluminum hydroxide could be reproduced in 
the clinical samples of ONS-3010 and Humira® treated subjects. 
Treatment resulted in a more than 99% reduction in detectable 
TNFα levels in the whole blood culture supernatant. The reduc-
tion in TNFα levels did not differ between the three treatment 
groups in terms of magnitude or duration. Surprisingly, whereas 
adalimumab inhibited LPS/aluminum hydroxide-induced 
IFNγ release in the preclinical in vitro experiment, this effect 
could not be confirmed in the clinical study. As described in the 
Section “Results,” the inter-individual variability in IFNγ levels 
was substantial, and a large number of data points was BLOQ 
(<114  pg/mL). Strikingly, a major difference in IFNγ release 
was observed between male and female subjects (baseline levels 
1308 and 144 pg/mL, respectively). These data are in contrast 
to studies reporting no significant differences in IFNγ cytokine 
levels between both sexes (39, 40), and we are not aware of 
studies reporting the existence of sex-dependent IFNγ release. 
The different responsiveness in IFNγ release observed in the 
current study upon TLR4/inflammasome stimulation may 
relate to sex differences in circulating cell populations produc-
ing IFNγ or hormonal influences that play a role in this specific 
immune response (41). IL-1β, IL-6, and IL-8 responses were 
comparable for the three treatment groups. In line with the 
results from the preclinical in vitro experiment, LPS/aluminum 
hydroxide-induced release of IL-1β and IL-6 was not inhibited 
by anti-TNFα treatment in the clinical study. In contrast, 
administration of adalimumab did result in a reduction of LPS/
aluminum  hydroxide-induced IL-8 release. A maximal decrease 
of approximately 30% was observed at day 15. Although this 
burning sensation upon injection at injection site, headache, and 
nasopharyngitis. In general, the AEs were evenly divided over 
the treatments, mild in severity, and self-limiting. In addition to 
PK, safety, and immunogenicity, the intended pharmacological 
activity of the compounds was assessed in this study using whole 
blood LPS/aluminum challenges. This PD endpoint was included 
to reduce the risk of late discovery of bio-non-similarity for the 
intended drug effect, even though this approach is rarely applied 
in biosimilarity trials in healthy volunteers. An LPS/aluminum 
challenge was used to induce TLR4-driven NFkB signaling and 
NALP3/NLRP3 inflammasome activation. Both pathways are 
implicated in the pathogenesis of autoimmune diseases for which 
Humira® is being prescribed.
Preceding the clinical study, the effect of TNFα blockade on 
LPS/aluminum hydroxide-induced cytokine release in whole 
blood samples was verified in vitro. TNFα blockade resulted in 
dramatically reduced TNFα levels (maximally 99%) measured in 
the culture supernatant. IFNγ release was also strongly affected, 
with a maximal reduction of 93%. Previous studies also described 
TaBle 4 | confirmed and neutralizing antibodies.
confirmed antibodies neutralizing antibodies
Ons-3010 (n = 63)a humira® eU (n = 62)a humira® Us (n = 65)a Ons-3010 (n = 66) humira® eU (n = 65)b humira® Us (n = 66)
Day 15 20 17 13 8 8 3
Day 43 31 28 25 31 24 24
Day 57 39 38 37 41 37 37
Samples with normalized inhibition <0.886 were deemed positive for neutralizing antibodies. Subjects with a positive result for confirmed (a) and neutralizing (b) antibodies pre-dose 
were excluded.
FigUre 4 | TnFα (a), il-1β (B), il-6 (c), and il-8 (D) release after ex vivo lPs/aluminum hydroxide stimulation of blood samples collected from 
clinical study participants [change from baseline (cfb) %, with sD].
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effect size is limited and the inter-individual variability rela-
tively large, the timing of the IL-8 decrease suggests a causal 
relationship with the anti-TNFα treatment. This observation 
may be explained by the role of TNFα as an autocrine stimulator 
and a potent paracrine inducer of inflammatory cytokines (3), 
although the duration of the IL-8 reduction (i.e., shorter than 
the TNFα reduction) and the absent effect on IL-6 release raises 
questions about the responsible mechanism.
The advised Humira® dose for the treatment of rheumatoid 
arthritis is 40  mg (11). Our data demonstrate that 40  mg 
adalimumab results in maximally reduced TNFα levels in LPS-/
aluminum-exposed whole blood cultures, persisting for at least 
a month (Figure  4A). During this period, the corresponding 
adalimumab concentrations ranged from 3800 (Tmax) to 1050 ng/
mL (day 36, Figure 2). A comparable adalimumab concentration 
range also resulted in a maximal reduction of TNFα levels in our 
preclinical in vitro experiment (Figure 3), which demonstrates 
the excellent translatability between in vitro and ex vivo TNFα 
blocking in an LPS/aluminum challenge model.
Importantly, our in vitro TNFα blockade experiment shows 
that a dose of 40  mg Humira®, which is applied in clinical 
practice, is a rational dose based on the observed PD effects in 
this study: circulating adalimumab concentrations below 1 μg/
mL (Figure  2, after day 36) translated into a sub-maximal 
reduction of LPS-/aluminum-induced TNFα levels (Figure  4). 
Taken together, these data demonstrate the relevance of the LPS/
aluminum challenge to monitor Humira® effects and emphasize 
the value of whole blood challenges for monitoring of proximal 
drug effects in healthy volunteers, and potentially in the target 
population.
In conclusion, this healthy volunteer study demonstrated 
equivalence for PK endpoints and closely comparable PD bio-
marker profiles between ONS-3010 and the marketed Humira®. 
The immunogenicity profiles were well comparable between 
FigUre 5 | neutrophil (a) and lymphocyte (B) count with sD; vertical line at day 1 denotes dosing.
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treatment groups, and there were no indications for differences 
in routine safety parameters. These data are promising for the 
further clinical development of ONS-3010 and underline the 
value of incorporation of PD measures in early clinical phase 
biosimilar trials.
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